Latest Commercialisation Strategy News

Page 4 of 8
Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.
Ada Torres
Ada Torres
29 Aug 2025
Rhythm Biosciences has formalised a strategic co-marketing partnership with the Know Your Lemons Foundation to promote its geneType Breast Cancer Risk Assessment Test, expanding access to early detection tools for women in the US and Australia.
Ada Torres
Ada Torres
28 Aug 2025
Impact Minerals’ 50%-owned Alluminous Pty Ltd advances its proprietary HiPurA® High Purity Alumina technology with new leadership and pilot plant commissioning, attracting strong customer interest.
Maxwell Dee
Maxwell Dee
20 Aug 2025
AnteoTech has appointed Merrill Gray as its new Managing Director and CEO following a successful interim period, while issuing over 22 million shares to staff under its FY2025 incentive program.
Maxwell Dee
Maxwell Dee
19 Aug 2025
AnteoTech has mutually terminated its A$1.4 million Queensland government grant to avoid costly co-investment, opting instead for cheaper third-party testing to advance its Ultranode™ battery technology.
Victor Sage
Victor Sage
15 Aug 2025
Green360 Technologies has successfully raised A$4 million through a share placement to fund the commercialisation and scaling of its innovative low-carbon cement technology, supported by institutional investors and strengthened leadership.
Maxwell Dee
Maxwell Dee
11 Aug 2025
EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.
Ada Torres
Ada Torres
5 Aug 2025
Nanollose Limited has completed a successful pilot manufacturing run blending its Nullarbor-20 fibre with wool, raised $1.05 million through an entitlement issue, and appointed Andrew Moullin as CEO to drive its commercialisation strategy.
Maxwell Dee
Maxwell Dee
31 July 2025
Tryptamine Therapeutics has initiated the first-ever clinical trial using IV-infused psilocin to treat Binge Eating Disorder, with patient dosing set to begin shortly and results expected by year-end.
Ada Torres
Ada Torres
31 July 2025
Terragen Holdings reports rapid customer growth for its new dry probiotics, secures a US patent, and posts promising crop trial results, signaling strong momentum in its agricultural biotech offerings.
Ada Torres
Ada Torres
31 July 2025
Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.
Ada Torres
Ada Torres
29 July 2025
ClearVue Technologies has appointed Douglas Hunt as its permanent Global CEO, unveiling a refreshed leadership team focused on scaling sales, manufacturing, and product innovation. The new executives have agreed to sub-market pay until the share price hits 35 cents, signaling strong alignment with shareholder interests.
Sophie Babbage
Sophie Babbage
28 July 2025